ReproCELL acquires the iPS Cell Business unit of Stemgent

Japan-based ReproCELL (Jasdaq: 4978) is to acquire the iPS Cell Business unit of Privately-held US firm Stemgent. This acquisition allows the ReproCELL Group to expand the product line-ups of its iPS cell business and establish technical advantages, promoting great differentiation. Financial terms of the transaction were not disclosed.

Stemgent has succeeded in launching many worldwide leading iPS cell research reagent products including mRNA reprogramming kit, xeno-free culture media, and specialty chemicals for cell differentiation, and has established a world-famous, proven and trusted brand in the iPS cell field.

Through the acquisition, ReproCELL Group can offer a wide variety of products with full coverage of iPS cell technologies, while also strengthening its sales channel and marketing function in the USA. In addition, the iPS Cell Business unit of Stemgent has a broad network of academic researchers including a strong scientific advisory board in the USA, while ReproCELL has a wide academic network in Japan with a strong scientific advisory board, as well as its founder Prof Nakatsuji at Kyoto University and Prof Nakauchi at the University of Tokyo.